Linked Life Data

20489194

Source:http://linkedlifedata.com/resource/pubmed/id/20489194

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-5-21
pubmed:abstractText
In the majority of patients, existing therapies for neuropathic pain are far from effective. Furthermore, all current treatments are symptomatic rather than disease-modifying or curative. A range of therapeutic modalities is emerging, targeting a variety of mechanisms, but choosing the best target and evaluating the resulting therapies against the many types of neuropathic pain disorders is not an easy task. In this article, we suggest a shift in emphasis of the drug discovery paradigm toward unbiased evaluation of the particular neurobiological mechanisms contributing to neuropathic pain in individual patients. Genomewide association studies and other discovery science approaches to identify significant novel targets should be given priority as should the development of increasingly sophisticated tools for measuring and categorizing neuropathic pain.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1549-490X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
24-9
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Future directions in neuropathic pain therapy: closing the translational loop.
pubmed:affiliation
University of Wisconsin-Madison, Madison, Wisconsin, USA.
pubmed:publicationType
Journal Article, Review